Cadila Healthcare has reported results for the quarter ended June 30, 2011
The company’s net profit for the quarter has dipped by 23.01% at Rs 152.93 crore as compared to Rs 198.64 crore for the quarter ended June 30, 2010. Its total Income too has decreased by 1.07% to Rs 790.52 crore for the quarter under review from Rs 799.11 crore for the corresponding quarter of the previous year.
On Consolidated basis, the Group ‘s net profit has registered a gain of 15.38% at Rs 229.82 crore for the quarter ended June 30, 2011 as compared to Rs 199.18 crore for the quarter ended June 30, 2010. Its total Income has increased by 10.15% to Rs 1252 crore for the quarter from Rs 1136.65 crore for the similar quarter of the previous year.
Cadila Pharmaceuticals focuses on various areas, such as formulations (human & veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1693.15 |
| Dr. Reddys Lab | 1221.25 |
| Cipla | 1230.75 |
| Zydus Lifesciences | 939.20 |
| Lupin | 2326.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: